Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Smoldering Multiple Myeloma

• Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple My
• Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
• A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
• CAR- PRISM (PRecision Intervention Smoldering Myeloma)
• Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
• Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
• Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
• Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
• A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
• Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
• Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
• DARA RVD For High Risk SMM
• Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
• Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
• Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
• Denosumab for Smoldering Multiple Myeloma
• A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
• Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
• Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
• A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
• Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
• A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
• Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
• Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
• Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
• Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
• A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
• Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
• UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
• A Phase II Study of BI-505 in Smoldering Multiple Myeloma
• MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
• Imaging Studies and the Development of Multiple Myeloma
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
• Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
• A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
• A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
• Imaging in MGUS, SMM and MM
• Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
• Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
• Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
• Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
• Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
• Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
• Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma